Procter & Gamble (P&G) announced on August 4, 2026, its definitive agreement to acquire Thorne, a leading manufacturer of science-backed dietary supplements and health products, for $3.8 billion. This significant transaction represents a substantial return on investment for Thorne’s current owner, private equity firm L Catterton, signaling a robust valuation and a testament to Thorne’s accelerated growth trajectory. The deal is anticipated to close later this year, subject to customary regulatory approvals, marking a pivotal moment for both P&G’s expanding health portfolio and the rapidly evolving nutraceutical sector.
Thorne will integrate into P&G’s health care division, joining a portfolio that includes established brands such as Align Probiotic and Metamucil, and notably, New Chapter, another prominent player in the natural products industry. This strategic acquisition underscores P&G’s commitment to diversifying and strengthening its presence in the premium health and wellness market, a sector experiencing sustained consumer demand for science-backed, high-quality products.
A Legacy of Science and Growth: Thorne’s Journey
Founded over four decades ago in the Pacific Northwest by Al Czap, Thorne initially established its roots in Sandpoint, Idaho. For many years, the company operated with a strong focus on the practitioner channel, serving healthcare professionals with meticulously formulated supplements. This foundation was built on a commitment to scientific rigor and product quality, differentiating Thorne in a crowded marketplace.
A transformative shift in Thorne’s operational and strategic direction occurred in 2018 under the leadership of former CEO Paul Jacobsen. The company relocated to a state-of-the-art, 240,000-square-foot manufacturing facility in Summerville, South Carolina. This move coincided with a strategic expansion beyond its traditional practitioner base to encompass direct-to-consumer retail channels and the development of advanced consumer health testing services. This pivot proved to be a significant catalyst for growth.
The company’s burgeoning success led to its initial public offering (IPO) in 2021, with a valuation of $525 million. In 2023, Thorne was taken private again by the private equity firm L Catterton in a deal valued at $680 million. Under the leadership of former Vitamin Shoppe CEO Colin Watts, Thorne continued its expansion, particularly into the broader consumer market. Industry projections indicated Thorne’s full-year 2025 revenue would surpass $500 million, highlighting its impressive financial performance.
Private Equity’s Role in Value Creation
The recent history of Thorne serves as a compelling case study in how private equity ownership can strategically enhance a brand’s value and market reach. Scott Steinford, CEO of Texas-based contract manufacturer PreMark Health Sciences, a seasoned executive with experience guiding brands through acquisition phases, commented on Thorne’s trajectory.
"Everybody has reservations about what private equity firms do when they acquire a brand," Steinford stated in an interview with SupplySide Supplement Journal. "However, not every private equity transaction is detrimental. Thorne successfully transitioned from a largely under-the-radar practitioner channel brand to a significant retail presence in an impressively short period. This was driven by aggressive, expansionist strategic thinking."
Steinford further elaborated on Thorne’s attractiveness as an acquisition target. "From a strategic standpoint, Thorne was not only appealing due to its exceptional recent performance but also because it is positioned within a market sector poised for continued robust growth," he explained. "This acquisition reinforces the burgeoning trend of proactive healthcare taking center stage in our global healthcare systems. It’s tangible proof that this concept is gaining worldwide recognition."
New Chapter’s Success Under P&G: A Precedent for Thorne
The historical performance of New Chapter, another prominent natural supplement brand acquired by P&G in 2012, offers a potential blueprint for Thorne’s future under P&G’s stewardship. Marc Brush, a veteran industry strategy consultant and former editor of Informa’s Nutrition Business Journal, believes that New Chapter’s experience provides valuable insight.
"The New Chapter acquisition occurred in 2012, which is ample time for most large consumer packaged goods (CPG) companies to either succeed or falter," Brush observed. "Despite some initial friction between P&G management and New Chapter founders Paul and Barbi Schulick, who departed their management roles in 2018, most industry observers acknowledge that P&G has managed New Chapter effectively. While Paul Schulick expressed concerns in a past interview about potential pressure to cut corners for profit, the overall trajectory of New Chapter under P&G has been positive, instilling confidence for P&G to make another significant investment of this magnitude."
The period between 2013 and 2018 saw P&G’s earnings face some headwinds. However, the sustained presence and continued growth of New Chapter within P&G’s portfolio suggest a capacity for the consumer giant to integrate and nurture brands rooted in natural product principles. Brush’s assessment is that P&G has demonstrated a proficiency in maintaining the core equity of acquired supplement brands, a crucial factor for long-term success.
Strategic Rationale and Valuation Analysis
The substantial $3.8 billion valuation P&G is placing on Thorne reflects a confluence of factors, including the explosive growth of the health and wellness market, Thorne’s proven track record, and its strategic positioning for future expansion. Brush offered an analytical perspective on the premium price.
"The premium P&G is paying for Thorne is a testament to both the anticipated continued growth of the supplement category and the robust, professional infrastructure that Thorne’s various leadership teams have meticulously built over its history," Brush stated. He pointed to Thorne’s projected 2026 sales of $650 million, which places the acquisition multiple in the realm of approximately 5.8 times revenue, a figure he described as "super frothy" in the current M&A landscape. However, Brush added that if Thorne achieves its full growth potential, this valuation could align more closely with prevailing M&A norms in the near future.
"The return for L Catterton is impressive, but this was a development that occurred over years," Brush continued. "Thorne has undergone distinct evolutionary phases: its initial focus on quality under Al Czap, a deep grounding in high science during the Paul Jacobson era, and more recently, cracking the consumer code online with Colin Watts and his team. The high price is largely predicated on this last phase. Few brands have successfully navigated the transition from clinics and practitioners to online platforms like Amazon and direct-to-consumer channels as effectively as Thorne. This success provides P&G with confidence that Thorne has a clear path toward achieving $1 billion in annual revenues."
The ability of Thorne to significantly scale its online sales channels was likely a critical factor in P&G’s decision-making process, signaling a strong understanding of modern consumer purchasing habits.
Navigating the Challenges of Corporate Integration
While the acquisition of innovative brands by large corporations is a recurring theme in business history, it is often fraught with challenges. The history of megacorporations integrating smaller, agile companies is indeed littered with cautionary tales where brand identity and innovation were diluted or lost. However, Brush remains cautiously optimistic about Thorne’s prospects.
"Most of these high-profile deals can falter over time, which is precisely why the New Chapter precedent is so important," Brush emphasized. "P&G has, in my view, demonstrated a greater aptitude than many of its peers in preserving the genuine brand equity of its acquisitions within the supplement sector. Nevertheless, this will remain a significant challenge. At these valuation levels, Thorne will need to sustain its rapid growth. The daily decisions made to protect product quality and consumer trust are difficult to consistently uphold over the long term, especially under the pressures of a large corporate structure."
The integration of Thorne into P&G’s vast operational framework will require a delicate balance. P&G will need to leverage its scale, resources, and distribution capabilities to further propel Thorne’s growth while safeguarding the brand’s core values of scientific integrity, quality, and consumer trust that have been instrumental in its success. The company’s demonstrated experience with New Chapter suggests a strategic approach that prioritizes brand preservation alongside commercial expansion.
Broader Implications for the Supplement Industry
The acquisition of Thorne by Procter & Gamble is more than just a significant financial transaction; it represents a powerful endorsement of the burgeoning health and wellness sector by a global CPG titan. It signals a growing recognition among major corporations of the long-term potential and increasing sophistication of the dietary supplement market. As consumers continue to prioritize preventative health and seek personalized wellness solutions, companies like Thorne, with their science-backed approach and direct consumer engagement, are becoming increasingly valuable assets.
Thorne’s commitment to NSF Certified for Sport products, exemplified by its recent partnership with WNBA star Napheesa Collier to champion these offerings, highlights its dedication to transparency and quality assurance. This emphasis on third-party certification is a critical differentiator in a market where consumer trust is paramount. P&G’s acquisition is likely to further amplify these quality standards and extend their reach to a broader consumer base.
The strategic move by P&G also suggests a potential shift in how traditional CPG companies are approaching the health and wellness space. Rather than solely relying on in-house innovation, acquiring established, high-growth brands with strong scientific foundations and direct consumer relationships appears to be a preferred strategy. This could lead to further consolidation within the supplement industry as other large players seek to replicate P&G’s success.
Furthermore, the deal underscores the increasing importance of direct-to-consumer (DTC) channels and sophisticated digital marketing strategies. Thorne’s ability to successfully transition from a practitioner-focused business to a prominent online retailer has been a key driver of its valuation. P&G’s integration of Thorne will likely involve leveraging its extensive marketing expertise to further enhance Thorne’s digital footprint and consumer engagement.
In conclusion, the acquisition of Thorne by Procter & Gamble for $3.8 billion marks a significant milestone in the evolution of the supplement industry. It is a testament to Thorne’s remarkable growth, its unwavering commitment to science and quality, and the increasing strategic importance of proactive health and wellness solutions. The success of this integration will be closely watched as a bellwether for future CPG investments in the dynamic and expanding health supplement market.
